Sigilon Therapeutics, Inc.:
Platform cell therapy company focusing on several chronic diseases (hemophilia, T1D, lysosomal storage disorders); 5 INDs exp in the next 2 years; 1st IND in Jan 2020 (Hemophilia A). Eli Lilly collaboration in T1D ($75m initial commitment, $410 milestones & single to double digit royalties). Engineering cells to produce crucial proteins/enzymes/etc; encapsulate cells in alginate sphere covalently bonded w/coating that prevents fibrosis & rejection; coating dev'd at Bob Langer's Lab at MIT. Flagship Pioneering-backed; $150M raised to date.
US - New England
100 Binney Street
Cambridge, MA 02142
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.